First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients Journal Article
| Authors: | Abida, W.; Bajorin, D. F.; Rosenberg, J. E. |
| Article Title: | First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients |
| Abstract: | Metastatic urothelial carcinoma is primarily a disease of the elderly, with a median overall survival of approximately 15 months. Cisplatin-based combination chemotherapy is standard first-line treatment for eligible patients, with carboplatin-based regimens used as an alternative for patients considered unfit to receive cisplatin. Prognostic models incorporating clinical risk factors have been validated, and molecular characteristics that predict for treatment response are under investigation. This review summarizes the current status of first-line treatment of metastatic urothelial carcinoma in platinum-eligible patients as well as prognostic and predictive models in this disease. Copyright © 2015 Elsevier Inc. All rights reserved. |
| Keywords: | treatment outcome; mortality; antineoplastic agent; metastasis; antineoplastic combined chemotherapy protocols; pathology; urinary bladder neoplasms; prognostic factors; neoplasm metastasis; platinum; humans; prognosis; human; urothelial carcinoma, metastatic; platinum chemotherapy |
| Journal Title: | Hematology/Oncology Clinics of North America |
| Volume: | 29 |
| Issue: | 2 |
| ISSN: | 0889-8588 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-04-01 |
| Start Page: | 319 |
| End Page: | 328 |
| Language: | English |
| DOI: | 10.1016/j.hoc.2014.10.005 |
| PUBMED: | 25836937 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 August 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work